132 related articles for article (PubMed ID: 8268395)
1. Synthesis of the enantiomers of the bioreductively-activated cytotoxin RSU-1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitro.
Naylor MA; Threadgill MD; Showalter HD; Stratford IJ; Stephens MA; Fielden EM; Adams GE
Drug Des Discov; 1993; 10(3):249-55. PubMed ID: 8268395
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins.
Jenkins TC; Naylor MA; O'Neill P; Threadgill MD; Cole S; Stratford IJ; Adams GE; Fielden EM; Suto MJ; Stier MA
J Med Chem; 1990 Sep; 33(9):2603-10. PubMed ID: 2391699
[TBL] [Abstract][Full Text] [Related]
3. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
Cole S; Stratford IJ; Adams GE; Fielden EM; Jenkins TC
Radiat Res; 1990 Oct; 124(1 Suppl):S38-43. PubMed ID: 2236508
[TBL] [Abstract][Full Text] [Related]
4. 2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivatives.
Naylor MA; Threadgill MD; Webb P; Stratford IJ; Stephens MA; Fielden EM; Adams GE
J Med Chem; 1992 Sep; 35(19):3573-8. PubMed ID: 1404237
[TBL] [Abstract][Full Text] [Related]
5. A new class of analogues of the bifunctional radiosensitizer alpha-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines.
Suto MJ; Stier MA; Werbel LM; Arundel-Suto CM; Leopold WR; Elliott WE; Sebolt-Leopold JS
J Med Chem; 1991 Aug; 34(8):2484-8. PubMed ID: 1875345
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility.
Hay MP; Lee HH; Wilson WR; Roberts PB; Denny WA
J Med Chem; 1995 May; 38(11):1928-41. PubMed ID: 7783125
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of 2-nitroimidazoles with variable alkylating and acylating functionality.
Winters T; Sercel A; Suto C; Elliott W; Leopold W; Leopold J; Showalter H
Chem Pharm Bull (Tokyo); 2014; 62(3):301-3. PubMed ID: 24583786
[TBL] [Abstract][Full Text] [Related]
8. Nitroimidazoles as anti-tumor agents.
Liu K; Zhu HL
Anticancer Agents Med Chem; 2011 Sep; 11(7):687-91. PubMed ID: 21521156
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
Threadgill MD; Webb P; O'Neill P; Naylor MA; Stephens MA; Stratford IJ; Cole S; Adams GE; Fielden EM
J Med Chem; 1991 Jul; 34(7):2112-20. PubMed ID: 2066984
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers.
Hay MP; Wilson WR; Moselen JW; Palmer BD; Denny WA
J Med Chem; 1994 Feb; 37(3):381-91. PubMed ID: 8308864
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis inhibitor TX-1898: syntheses of the enantiomers of sterically diverse haloacetylcarbamoyl-2-nitroimidazole hypoxic cell radiosensitizers.
Jin CZ; Nagasawa H; Shimamura M; Uto Y; Inayama S; Takeuchi Y; Kirk KL; Hori H
Bioorg Med Chem; 2004 Sep; 12(18):4917-27. PubMed ID: 15336271
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological activity of anti-angiogenic hypoxic cell radiosensitizer haloacetylcarbamoyl-2-nitroimidazoles.
Hori H; Jin CZ; Kiyono M; Kasai S; Shimamura M; Inayama S
Bioorg Med Chem; 1997 Mar; 5(3):591-9. PubMed ID: 9113337
[TBL] [Abstract][Full Text] [Related]
13. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
Cole S; Stratford IJ; Fielden EM; Adams GE; Leopold W; Elliott W; Suto M; Sebolt-Leopold J
Int J Radiat Oncol Biol Phys; 1992; 22(3):545-8. PubMed ID: 1735694
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of potential dual-acting radiation sensitizer antineoplastic agents: 2,2-dimethylphosphoraziridines containing 2-nitroimidazoles or other electron-affinic moieties.
Perlman ME; Dunn JA; Piscitelli TA; Earle J; Rose WC; Wampler GL; MacDiarmid JE; Bardos TJ
J Med Chem; 1991 Apr; 34(4):1400-7. PubMed ID: 2016716
[TBL] [Abstract][Full Text] [Related]
15. Electron-affinic radiosensitizers possessing NPSH-reactive side chains: cytotoxicity and radiosensitizing activity towards hypoxic EMT6 cells in vitro.
Zhou L; Nishimoto S
Int J Radiat Biol; 1995 Mar; 67(3):335-46. PubMed ID: 7897282
[TBL] [Abstract][Full Text] [Related]
16. Synergistic enhancement of the efficacy of the bioreductively activated alkylating agent RSU-1164 in the treatment of prostatic cancer by photodynamic therapy.
Henry JM; Isaacs JT
J Urol; 1989 Jul; 142(1):165-70. PubMed ID: 2733098
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic transforming potential of nitroimidazole radiosensitizers.
Hall EJ; Hei TK
Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1231-4. PubMed ID: 2523882
[TBL] [Abstract][Full Text] [Related]
18. Dual-function radiosensitizers. Alpha-[[(2-bromoethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanol and related compounds: preparation via an aziridine equivalent.
Suto MJ; Stier MA; Werbel LM
J Med Chem; 1991 Mar; 34(3):1207-9. PubMed ID: 2002462
[TBL] [Abstract][Full Text] [Related]
19. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
Cole S; Stratford IJ; Bowler J; Nolan J; Wright EG; Lorimore SA; Adams GE
Int J Radiat Oncol Biol Phys; 1991 Jul; 21(2):387-95. PubMed ID: 2061115
[TBL] [Abstract][Full Text] [Related]
20. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.
Bremner JC
Cancer Metastasis Rev; 1993 Jun; 12(2):177-93. PubMed ID: 8375020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
